SCHEMBL459431

SCHEMBL459431

O=S(=O)(Cl)C1CCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18760092 1.00
SCHEMBL28037335 1.00
SCHEMBL25420216 0.86 CXCR2 (0.30)
SCHEMBL1444798 0.84 CA12 (0.31)
SCHEMBL14860931 0.78
SCHEMBL28812979 0.78
SCHEMBL8311349 0.75
SCHEMBL4764165 0.75
SCHEMBL4767756 0.75
SCHEMBL24248222 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10398677-B2 N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B JANSSEN SCIENCES IRELAND UC (IE) 2019-09-03 US claimed
US-20180153857-A1 N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UC (IE) 2018-06-07 US claimed
US-20260109711-A1 MACROCYCLIC SULFONAMIDE MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-23 US disclosed
EP-4720076-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. Lundbeck A/S (DK) 2026-04-08 EP disclosed
US-12590106-B2 Spiromacrocyclic orexin 2 receptor agonists H. LUNDBECK A/S (DK) 2026-03-31 US disclosed
US-20250263422-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2025-08-21 US disclosed
WO-2025136811-A1 CHEMICAL COMPOUNDS AND USES THEREOF IDEAYA BIOSCIENCES, INC. (US) 2025-06-26 WO disclosed
US-12258327-B2 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors YUHAN CORPORATION (KR) 2025-03-25 US disclosed
US-20240425521-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2024-12-26 US disclosed
US-20240400564-A1 INHIBITORS OF THE MENIN-MLL INTERACTION SYNDAX PHARMACEUTICALS, INC. 2024-12-05 US disclosed
WO-2024246285-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2024-12-05 WO disclosed
WO-2013177224-A1 N-SUBSTITUTED BENZAMIDES AND THEIR USE IN THE TREATMENT OF PAIN GENENTECH, INC. (US) 2013-11-28 WO disclosed
US-20130317001-A1 N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2013-11-28 US disclosed
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators Synchronicity Pharma, Inc. 2013-11-14 US disclosed
WO-2013170186-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS RESET THERAPEUTICS, INC. (US) 2013-11-14 WO disclosed
EP-2651906-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE Cocrystal Discovery, Inc. (US) 2013-10-23 EP disclosed
WO-2013045516-A1 VIRAL REPLICATION INHIBITORS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2013-04-04 WO disclosed
US-20120183496-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL DISCOVERY, INC. (US) 2012-07-19 US disclosed
WO-2012083105-A1 INHIBITORS OF HEPATITIS C VIRUS POLYMERASE COCRYSTAL DISCOVERY, INC. (US) 2012-06-21 WO disclosed
WO-2011147951-A1 CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS PROSIDION LIMITED (GB) 2011-12-01 WO disclosed